Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
CHENGDU, China, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development. Dr. Jackson will work closely with the Company’s CEO, Joshua Liang, to accelerate the development of Clover’s existing pipeline candidates and nominate new product candidates.
"We are excited to welcome Nick to Clover’s leadership team. His extensive experience in leading vaccine and immunotherapeutic research and development will be invaluable as we continue to advance and expand our portfolio of innovative product candidates," stated Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals. "With his deep understanding of the COVID-19 vaccine market, we look forward to working with Nick to complete the regulatory submissions for SCB-2019 (CpG 1018/Alum), continue development of SCB-2019 as a universal booster, and pursue the development of next-generation COVID-19 vaccine candidates utilizing Trimer-Tag™."
"I am honored to join Clover and look forward to helping expand its global R&D capabilities and innovative pipeline of vaccines and oncology therapies. Clover’s protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has demonstrated significant vaccine efficacy against variants while achieving a potentially best-in-field safety profile, making it an important tool in the global fight against COVID-19," said Dr. Nicholas Jackson. "In parallel with completing universal booster development and regulatory submissions for SCB-2019 (CpG 1018/Alum), I look forward to leading new R&D initiatives across the vaccine and oncology portfolios to further strengthen Clover’s pipeline and deliver innovative new product candidates to populations in need."
Dr. Jackson has spent over 22 years in vaccine and immunotherapeutic research and development roles, leading multiple successful global programs in bacterial, viral and non-infectious disease targets. In his most recent role with the Centre for Epidemic Preparedness and Innovation (CEPI), Nicholas was the Head of Vaccine Programs and Technology for Research and Development and also served as the Managing Director of CEPI's China office in Shanghai. Prior to his work at CEPI, Dr. Jackson was Vice President, Head of Global Research for Sanofi Pasteur, responsible for leading vaccine research and early development activities globally. Before Sanofi Pasteur, Nicholas held vaccine and immunotherapeutic development roles at Pfizer, IAVI and GlaxoSmithKline, where he oversaw R&D programs, global clinical trials and collaborations.
Dr. Nicholas Jackson holds a Bachelor of Science degree from Oxford Brookes University, a Master of Science from the London School of Hygiene & Tropical Medicine, and a doctorate from the University of Warwick in the field of viral immunology.
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2.
Clover Forward-looking Statements
This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.
SVP, Public Affairs
VP, Investor Relations